Despite Pfizer's assertion that the claims are baseless, the company has deemed the settlement as the most suitable resolution to the long-standing dispute. Read more: EU: Pfizer offers concessions for Hospira deal The lawsuit, brought forth by drug purchasers including Rochester Drug Co-Operative and Stephen L. LaFrance Holdings, alleges that Wyeth and Teva engaged in anticompetitive practices, leading to inflated prices for Effexor XR. The plaintiffs claim that Wyeth made what is known as a "reverse payment" to Teva to delay the market entry of a generic version of the drug, resulting in consumers paying higher prices. While Wyeth has opted to settle, the case against Teva will proceed. Teva, for its part, has consistently denied the allegations. The settlement, agreed upon by both Wyeth and the plaintiffs, aims to avoid further legal expenses and the uncertainties of a trial.